Impact of a dual glucose‐dependent insulinotropic peptide/ glucagon‐like peptide ‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis
Einfluss des dualen GIP/GLP-1-Rezeptoragonisten Tirzepatid auf die Herzfrequenz bei Patient:innen mit Typ-2-Diabetes: systematische Übersichtsarbeit sowie paarweise und Netzwerk-Metaanalyse
Diabetes, Obesity and Metabolism · 2024-02 · 26 (2) · 548-556
DOI: 10.1111/dom.15342 ↗Auf einen Blick
Acht Artikel zeigen: Tirzepatid war mit einem stärkeren Anstieg der Herzfrequenz verbunden als Kontrollgruppen. Der Effekt war bei 15 mg am ausgeprägtesten.
Fragestellung
Welchen Einfluss hat Tirzepatid auf die Herzfrequenz bei Erwachsenen mit Typ-2-Diabetes, und besteht ein Dosis-Wirkungs-Zusammenhang?
Methode
Systematische Übersicht mit paarweiser und Netzwerk-Metaanalyse von RCTs; Suche in PubMed, Web of Science, Embase, Cochrane Library und Studienregistern.
Ergebnisse
8 Artikel. Gegenüber der kombinierten Kontrollgruppe stieg die Herzfrequenz unter Tirzepatid stärker an: MD 1,82 (95 %-KI 0,75–2,89). Gegenüber GLP-1RAs: MD 2,29 (95 %-KI 1,00–3,59); gegenüber nicht-GLP-1RAs: MD 1,58 (95 %-KI 0,26–2,91).
Schlussfolgerung der Autor:innen
Die Studie zeigte einen stärkeren Anstieg der Herzfrequenz unter Tirzepatid als unter Kontroll-, GLP-1RA- und nicht-GLP-1RA-Gruppen; 15 mg hatte den stärksten Einfluss. Weitere Forschung zu den Folgen des Anstiegs ist erforderlich.
Kernaussagen
- Tirzepatid erhöhte die Herzfrequenz stärker als die Kontrollgruppe.
- 15 mg hatte den stärksten Effekt auf die Herzfrequenz.
- Die Autor:innen berichten einen Dosis-Wirkungs-Zusammenhang.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.10.2023. Verfasst von Yucheng Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Translation Medicine Center, Peking Union Medical College…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Beijing Municipal Natural Science Foundation, CAMS Innovation Fund for Medical Sciences, National High Level Hospital Clinical Research Funding.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To evaluate the impact of a dual glucose‐dependent insulinotropic peptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide (TZP), and its potential dose‐response effect, on heart rate.
Methods
Articles were searched from PubMed, Web of Science, Embase, Cochrane Library, and clinical trials registries (ClinicalTrials.gov) databases. Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included. Six study arms were summarized from original research (TZP 5, 10 and 15 mg, GLP‐1 receptor agonists [GLP‐1RAs], insulin, placebo). The GLP‐1RA and non‐GLP‐1RA groups were combined to form a control group. Two reviewers independently extracted data and assessed the quality of each study. Mean differences (MDs) were calculated as effect estimates for continuous outcomes. Pairwise meta‐analyses and network meta‐analyses were conducted. The study protocol was prospectively registered (PROSPERO ID: CRD42023418551).
Results
Eight articles were included in this systematic review and meta‐analysis. The mean baseline heart rate ranged from 65.2 to 75.7 beats per minute. Pairwise meta‐analysis showed that, compared with combined the control group, there were significantly greater increases in heart rates in the TZP group (MD 1.82, 95% confidence interval [CI] 0.75, 2.89). Similar significant rises were identified when comparing TZP with GLP‐1RAs and non‐GLP‐1RAs (GLP‐1 RAs: MD 2.29, 95% CI 1.00, 3.59; non‐GLP‐1RAs: MD 1.58, 95% CI 0.26, 2.91). TZP 5 mg was associated with smaller increases in heart rates compared to TZP 10 mg and TZP 15 mg (TZP 10 mg: MD −0.97, 95% CI −1.79, −0.14; TZP 15 mg: MD −2.57, 95% CI −3.79, −1.35). TZP 10 mg increased heart rate less than TZP 15 mg (MD −1.5, 95% CI −2.38, −0.82). Network meta‐analysis indicated that TZP 15 mg was associated with significant increases in heart rate compared with TZP 5 mg (MD 2.53, 95% CI 1.43, 3.62), TZP 10 mg (MD 1.44, 95% CI 0.35, 2.53), GLP‐1RAs (MD 3.46, 95% CI 1.67, 5.25), insulin (MD 2.86, 95% CI 1.32, 4.41) and placebo (MD 2.96, 95% CI 1.36, 4.57).
Conclusions
Our study showed not only that there was a greater increase in heart rate in the TZP group than in the control, GLP‐1RA and non‐GLP‐1RA groups, but also that the 15‐mg dose of TZP had the strongest impact on increasing heart rates compared with the other five inventions, with a TZP dose‐response impact on heart rate. Further research on the effects of TZP treatment‐related increases in heart rate is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Translation Medicine Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical…
- Diabetes Research Center of Chinese Academy of Medical Sciences, Beijing, China.
- The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
ORCID-Profile: Huabing Zhang, Yuxiu Li
Förderung
- Beijing Municipal Natural Science Foundation
- CAMS Innovation Fund for Medical Sciences
- National High Level Hospital Clinical Research Funding
- National Natural Science Foundation of China
Zitieren
APA
Yang, Y., He, L., Liu, P., Wang, J., Yang, N., Li, Z., Ping, F., Xu, L., Li, W., Zhang, H., & Li, Y. (2024). Impact of a dual glucose‐dependent insulinotropic peptide/ glucagon‐like peptide ‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis. Diabetes, Obesity and Metabolism, 26(2), 548-556. https://doi.org/10.1111/dom.15342
Vancouver
Yang Y, He L, Liu P, Wang J, Yang N, Li Z, et al. Impact of a dual glucose‐dependent insulinotropic peptide/ glucagon‐like peptide ‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis. Diabetes, Obesity and Metabolism. 2024;26(2):548-556. doi:10.1111/dom.15342
BibTeX
@article{Yang2024,
author = {Yang, Yucheng and He, Liyun and Liu, Peng and Wang, Jialu and Yang, Na and Li, Ziyi and Ping, Fan and Xu, Lingling and Li, Wei and Zhang, Huabing and Li, Yuxiu},
title = {Impact of a dual glucose‐dependent insulinotropic peptide/ glucagon‐like peptide ‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {2},
pages = {548--556},
doi = {10.1111/dom.15342}
}
EUVIMED